![](https://www.rickilewis.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2JWQVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c8e481400e9ce0bd5da5be96e10c6ac93c225218/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFMZ0FXa0M0QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--d00c0b801be2eac628730b2b4ffb891cbdd69dfe/640px-snake-fang-venom.jpg)
A simple nasal spray that stops SARS-CoV-2 in its tracks?
That could block the coronavirus in the nose, before it can travel down to the lungs or be coughed onto another person, perhaps becoming a powerful partner to vaccines and therapeutics, and easy to administer, store, and ship.
It "could allow us to reduce transmission and be able to have a quick response to outbreaks in certain areas of the world," said Jeffrey Nau, CEO of Oyster Point Pharma, based in Princeton NJ. The company recently announced repurposing of the smoking-cessation pill Chantix™ (varenacline), as well as a second molecule in the same class, simpinicline, each as nasal sprays against COVID. The FDA approved Chantix, a Pfizer product, in 2006. Today nearly 400 clinical trials are exploring other uses.
To continue reading, go to Genetic Literacy Project, where this post first appeared.